Our findings demonstrate that targeting OFD1 in combination with olaparib leads to a synergistic anti-tumor effect in various PDAC models, including xenografts, orthotopic models, PDX and spontaneous KPC models. This evidence concerns the gene OFD1 and neoplasm.